FAST NEWS: Antengene Acquires Full Interest in Anti-Tumor Cancer Drug
The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) said on Wednesday it has agreed to acquire the remaining interest it doesn’t already hold in the anti-tumor drug ATG-037 from Calithera Biosciences (CALA.US), giving…
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
Discover hidden China stock gems in our weekly newsletter